强生 RYBREVANT FASPRO 联合疗法头颈鳞癌 Phase 1b/2 达 77% 缓解率，系重复报道无新增事实

Johnson & Johnson (JNJ) reported Phase 1b/2 results showing that RYBREVANT FASPRO combined with pembrolizumab and carboplatin demonstrated substantial anti-tumor activity in patients receiving first-line treatment for recurrent or metastatic head and neck squamous cell carcinoma (HNSCC).
The findings come from Cohort 5 of the Phase 1b/2 OrigAMI-4 study, which evaluated subcutaneous amivantamab and hyaluronidase-lpuj, marketed as RYBREVANT FASPRO, in combination with the PD-1 inhibitor pembrolizumab and up to six cycles of carboplatin chemotherapy.
Among 22 patients with HNSCC other than human papillomavirus (HPV)-associated oropharyngeal squamous cell carcinoma, the combination achieved a confirmed overall response rate of 77%, including complete responses in 14% of patients and partial responses in 64%.
Tumor shrinkage was observed in all evaluable patients in this group. Responses occurred at a median of 9.4 weeks, and 65% remained ongoing after a median follow-up of 10.6 months.
Median overall survival had not been reached at the time of analysis, and 77% of patients in this group were alive at one year.
Among the seven patients with HPV-associated oropharyngeal squamous cell carcinoma, the overall response rate was 29%.
RYBREVANT FASPRO contains amivantamab, a bispecific antibody designed to target epidermal growth factor receptor (EGFR) and mesenchymal-epithelial transition (MET).
These pathways are implicated in tumor growth and treatment resistance, with EGFR and MET overexpression reported in approximately 80% to 90% of HNSCC tumors.
The safety profile of RYBREVANT FASPRO combined with pembrolizumab and carboplatin was consistent with the known profiles of the individual agents.
The most common adverse events were anemia, reported in 73% of patients, hypoalbuminemia and thrombocytopenia, each in 63%, and stomatitis in 57%.
Administration-related reactions occurred in 13% of patients, with no Grade 3 or higher events reported.
The findings support continued evaluation of the combination in the ongoing pivotal Phase 3 OrigAMI-5 study.
Separately, an application for RYBREVANT FASPRO in later-line head and neck cancer is under Priority Review with the U.S. Food and Drug Administration.
The Cohort 5 results were presented as a rapid oral presentation at the European Society for Medical Oncology (ESMO) Congress 2026.
The findings expand the clinical development program for subcutaneous amivantamab beyond its established use in EGFR-mutated non-small cell lung cancer.
JNJ has traded between $184.66 and $281.07 over the past year.
The stock closed Friday's trading (October 23, 2026) at $263.81, down 1.42%.
In pre-market trading the stock is at $266.46, up 1.00%.
For comments and feedback contact: editorial@rttnews.com
Business News
October 16, 2026 16:06 ET Monthly consumer price inflation data and retail sales figures were the main news from the U.S. economy this week. In Europe, monthly GDP figures from the U.K. gained attention. External trade data from China was in focus in Asia. Elsewhere, the International Monetary Fund released its latest projections for the global economy.